<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343042</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-017</org_study_id>
    <nct_id>NCT02343042</nct_id>
  </id_info>
  <brief_title>Selinexor and Backbone Treatments of Multiple Myeloma Patients</brief_title>
  <acronym>STOMP</acronym>
  <official_title>A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will independently assess the efficacy and safety of 10 combination therapies in&#xD;
      11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients&#xD;
      with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM).&#xD;
      The combinations to be evaluated are:&#xD;
&#xD;
        -  Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)&#xD;
&#xD;
        -  Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete&#xD;
&#xD;
        -  Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete&#xD;
&#xD;
        -  Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd)&#xD;
&#xD;
        -  Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete&#xD;
&#xD;
        -  Arm 6: Selinexor + dexamethasone + carfilzomib (SKd)&#xD;
&#xD;
        -  Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM&#xD;
&#xD;
        -  Arm 8: Selinexor + dexamethasone + ixazomib (SNd)&#xD;
&#xD;
        -  Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd)&#xD;
&#xD;
        -  Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd)&#xD;
&#xD;
        -  Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd)&#xD;
&#xD;
      Selinexor pharmacokinetics:&#xD;
&#xD;
        -  PK Run-in (Days 1-14):&#xD;
&#xD;
      Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase&#xD;
      (i.e., Arm 4 [SPVd], Arm 6 [SKd], Arm 8 [SNd], Arm 9 [SPEd], Arm 10 [SBd], and Arm 11 [SDPd])&#xD;
      will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have&#xD;
      been enrolled to this period to evaluate the PK of selinexor before and after&#xD;
      co-administration with a strong CYP3A4 inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, clinical study with Dose Escalation (Phase 1) and&#xD;
      Expansion (Phase 2) to independently assess the MTD, efficacy , and safety of 10 combination&#xD;
      therapies in 11 arms in patients with RRMM and NDMM. Patients will be assigned to treatment&#xD;
      arms based on their diagnoses and treatment histories. For 9 patients, a PK Run-in period&#xD;
      will precede Cycle 1 (DLT evaluation) to assess selinexor PK when co-administered with a&#xD;
      strong CYP3A4 inhibitor. In the Dose Escalation Phase (Phase 1): (a) in Arm 1 (SPd), Arm 2&#xD;
      (SVd), and Arm 3 (SRd in RRMM), patients will be randomized to either QW or BIW selinexor&#xD;
      dosing cohorts; (b) in Arm 5 (SDd), patients will be sequentially assigned in blocks of 3 to&#xD;
      either QW or BIW selinexor dosing; (c) in Arm 4 (SPVd), Arm 6 (SKd), Arm 7 (Srd in NDMM), Arm&#xD;
      8 (SNd), Arm 9 (SPEd), Arm 10 (SBd), and Arm 11 (SDPd) patients will be assigned to QW&#xD;
      selinexor dosing.&#xD;
&#xD;
      Cohort 1.4 is included from Version 10 to study safety and tolerability of SPd with selinexor&#xD;
      40 mg QW, is lower than RP2D (ie, selinexor 60 mg QW) in combination with pomalidomide 4 mg.&#xD;
      Cohort 1.4 is a different expansion cohort from the one with RP2D (ie, Cohort 1.3). In Cohort&#xD;
      1.4, 20 patients will be enrolled in total.&#xD;
&#xD;
      Starting in protocol Version 8.0, patients enrolled to the Dose Escalation Phase of Arm 4&#xD;
      (SPVd), Arm 6 (SKd), Arm 8 (SNd), Arm 9 (SPEd), Arm 10 (SBd), and Arm 11 (SDPd) will first be&#xD;
      enrolled to a 14-day PK Run-in period (selinexor +/- clarithromycin) until 9 patients have&#xD;
      been enrolled. During this 14-day PK Run-in period, selinexor 40 milligrams (mg) will be&#xD;
      administered alone on Day 1, clarithromycin 500 mg twice daily (BID) will be administered on&#xD;
      Days 2-8, and selinexor 40 mg will again be administered on Day 8 with the morning&#xD;
      clarithromycin dose. Blood samples for PK analysis will be collected pre-dose and 1 (± 10&#xD;
      min), 1.5 (± 10 min), 2 (± 10 min), 3 (± 10 min), 4 (± 10 min), 5 (± 10 min), 6 (± 10 min), 8&#xD;
      (± 10 min), and 24 h (± 30 min) hours after selinexor is dosed on Day 1 (without&#xD;
      clarithromycin) and Day 8 (with clarithromycin). Patients will then proceed to the DLT&#xD;
      evaluation period that will begin after the completion of the 14-day PK Run-in period; this&#xD;
      day will be designated as Cycle 1 Day 1 (C1D1) in the Dose Escalation Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)</measure>
    <time_frame>12 months</time_frame>
    <description>MTD for once weekly and twice weekly selinexor dose cohorts in the 11 Arms will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>RP2D for each Arm will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of Selinexor</measure>
    <time_frame>Pre-dose, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)</time_frame>
    <description>Cmax of selinexor over a dosing interval when given with and without clarithromycin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor</measure>
    <time_frame>Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)</time_frame>
    <description>Total exposure of selinexor in the blood (AUC0-last) from the time of dosing to the last measurable concentration collected when given with and without clarithromycin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf)</measure>
    <time_frame>Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion): Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>ORR for each Arm independently. ORR to include stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR), according to the International Myeloma Working Group (IMWG) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion): Duration of response (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of response for each Arm. DOR is defined as the number of days from the date of the first evidence of objective response until progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Expansion): Clinical Benefit Rate (CBR)</measure>
    <time_frame>12 months</time_frame>
    <description>CBR is defined the point estimate of the percentage of patients in that arm who have a response of sCR, CR, VGPR, PR or Minimal response (MR), as assessed by IMWG criteria.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">518</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 28 days&#xD;
Cohort 1.1: Selinexor (SEL) 60/80/100 mg orally (PO) once weekly (QW); Dexamethasone (DEX) 40 mg PO once weekly; Pomalidomide (POM) 2/3/4 mg PO Days 1-21.&#xD;
Cohort 1.2: SEL 40/60/80 mg PO twice weekly (BIW); DEX 20 mg PO twice weekly; POM 3/4 mg PO Days 1-21.&#xD;
Cohort 1.3: Selinexor, Dexamethasone and Pomalidomide will be dosed at RP2D-1.&#xD;
Cohort 1.4: SEL 40 mg PO QW; DEX 40 mg PO QW; POM 4mg PO once daily (QD) Days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 35 days&#xD;
Cohort 2.1: SEL 60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Bortezomib (BOR) 1.3 milligram per meter square (mg/m^2) subcutaneous (SC) once weekly.&#xD;
Cohort 2.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.&#xD;
Cohort 2.3: Selinexor, Dexamethasone and Bortezomib will be dosed at RP2D-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 28 days&#xD;
Cohort 3.1: SEL 40/60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Lenalidomide (LEN) 15/25 mg PO Days 1-21.&#xD;
Cohort 3.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; LEN 15/25 mg PO Days 1-21.&#xD;
Cohort 3.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor and Clarithromycin:&#xD;
For the first 9 patients enrolled into this dose escalation arm&#xD;
14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1&#xD;
Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.&#xD;
PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.&#xD;
Dose-escalation Phase:&#xD;
All patients enrolled into this Arm&#xD;
Each cycle is of 28 days.&#xD;
Cohort 4.1:&#xD;
SEL 40/60 mg PO once weekly; DEX 40 mg PO once weekly; POM 4 mg PO Days 1-21; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.&#xD;
Cohort 4.3: Selinexor, Dexamethasone, Pomalidomide, Velcade (Bortezomib) will be dosed at RP2D-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 28 days&#xD;
Cohort 5.1:&#xD;
SEL 80/100 mg PO once weekly; DEX 40 mg once weekly (IV or PO); DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.&#xD;
Cohort 5.2:&#xD;
SEL: 60 mg PO twice weekly; DEX: 40 mg weekly (IV or PO); DARA: 16 milligram per kilogram (mg/kg) IV infusion Cycle 1-2: Once. weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.&#xD;
Cohort 5.3: Selinexor, Dexamethasone and Daratumumab will be dosed at RP2D-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor and Clarithromycin:&#xD;
For the first 9 patients enrolled into this dose escalation arm&#xD;
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1&#xD;
Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.&#xD;
PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.&#xD;
Dose-Escalation Phase:&#xD;
All patients enrolled into this Arm&#xD;
Each cycle is of 28 days&#xD;
Cohort 6.1:&#xD;
SEL 40/60/80/100 mg PO once weekly on days 1, 8, 15, and 22; DEX 40 mg IV or PO once weekly; Carfilzomib (CAR) 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.&#xD;
Cohort 6.2:&#xD;
SEL 60/80/100 mg PO once weekly on days 1, 8, and 15; DEX 40 mg IV or PO once weekly; CAR 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.&#xD;
Cohort 6.3: Selinexor, Dexamethasone and Carfilzomib will be dosed at RP2D-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 28 days&#xD;
Cohort 7.1:&#xD;
SEL 40/60/80 mg PO once weekly; DEX 40 mg PO once weekly; LEN 25 mg PO Days 1-21.&#xD;
Cohort 7.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor &amp; Clarithromycin:&#xD;
For the first 9 patients enrolled into this dose escalation arm&#xD;
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1&#xD;
Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.&#xD;
PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.&#xD;
Dose-Escalation Phase:&#xD;
All patients enrolled into this Arm&#xD;
Each cycle is of 28 days&#xD;
Cohort 8.1:&#xD;
SEL 40/60/80/100 mg PO once weekly; DEX 20 mg PO twice weekly; IXA 3/4 mg PO once weekly.&#xD;
Cohort 8.3: Selinexor, Dexamethasone and Ixazomib will be dosed at RP2D-8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK Run-in Period: Selinexor and Clarithromycin:&#xD;
For the first 9 patients enrolled into this dose escalation arm&#xD;
14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1&#xD;
Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.&#xD;
PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.&#xD;
Dose-Escalation Phase:&#xD;
All patients enrolled into this Arm&#xD;
Each cycle is of 28 days&#xD;
Cohort 9.1:&#xD;
SEL 20/40/60 mg PO once weekly; DEX 28/20 mg PO twice weekly; POM 4 mg PO QD Days 1-21; Elotuzumab (ELO) 10/20 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.&#xD;
Cohort 9.3: Selinexor, Dexamethasone, Pomalidomide and Elotuzumab will be dosed at RP2D-9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cycle is of 21 days&#xD;
Cohort 10.1:&#xD;
SEL 40/60/80 mg PO once weekly on Days 1, 8, and 15; DEX 40 mg PO QW on Days 1, 8, and 15; Belantamab Mafodotin (BEL) 2.5 mg/kg IV infusion every 3 weeks (Q3W) Day 1 of each cycle.&#xD;
Cohort 10.3:&#xD;
Selinexor, Dexamethasone, and Belantamab Mafodotin will be dosed at RP2D-10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Cycle is of 28 days&#xD;
Cohort 11.1 SEL 40/60 mg PO once weekly on Days 1, 8, and 15; DEX total 40 mg weekly (IV or PO) single or divided doses on Days 1, 8, 15, and 22; POM 4 mg PO QW Days 1-21; DARA 16 mg/kg IV or SC QW on Days 1, 8, 15 and 22 of Cycles 1-2 and on Days 1 and 15 of Cycles 3-6, Day 1 of every Cycle greater than (&gt;6).&#xD;
Cohort 11.3 Selinexor, Dexamethasone, Pomalidomide, and Daratumumab will be dosed at RP2D-11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)</arm_group_label>
    <arm_group_label>11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)</arm_group_label>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)</arm_group_label>
    <arm_group_label>3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM</arm_group_label>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)</arm_group_label>
    <other_name>KPT-330</other_name>
    <other_name>XPOVIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)</arm_group_label>
    <arm_group_label>11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)</arm_group_label>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)</arm_group_label>
    <arm_group_label>3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM</arm_group_label>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)</arm_group_label>
    <other_name>Decadron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM</arm_group_label>
    <arm_group_label>7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)</arm_group_label>
    <arm_group_label>1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)</arm_group_label>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)</arm_group_label>
    <other_name>Pomalyst®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Subcutaneous Injection (single use vial)</description>
    <arm_group_label>2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)</arm_group_label>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)</arm_group_label>
    <arm_group_label>5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)</arm_group_label>
    <other_name>Darzalex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)</arm_group_label>
    <other_name>Ninlaro®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)</arm_group_label>
    <other_name>Empliciti®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)</arm_group_label>
    <arm_group_label>6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)</arm_group_label>
    <arm_group_label>8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab Mafodotin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)</arm_group_label>
    <other_name>BLENREP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent signed in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          2. Age greater than or equal to (≥) 18 years at the time of informed consent.&#xD;
&#xD;
          3. Histologically confirmed diagnosis with measurable disease for relapsed/refractory&#xD;
             myeloma.&#xD;
&#xD;
          4. Symptomatic MM, based on IMWG guidelines.&#xD;
&#xD;
          5. Patients must have measurable disease as defined by at least one of the following:&#xD;
&#xD;
               1. Serum M-protein ≥ 0.5 gram per deciliter (g/dL) by serum protein electrophoresis&#xD;
                  (SPEP) or, for immunoglobulin A (IgA) myeloma, by quantitative IgA&#xD;
&#xD;
               2. Urinary M-protein excretion at least 200 mg/24 hours&#xD;
&#xD;
               3. Serum free light chain (FLC) ≥ 100 milligram per liter (mg/L), provided that FLC&#xD;
                  ratio is abnormal&#xD;
&#xD;
               4. If SPEP is felt to be unreliable for routine M-protein measurement (example, for&#xD;
                  IgA MM), then quantitative immunoglobulin (Ig) levels by nephelometry or&#xD;
                  turbidometry are acceptable&#xD;
&#xD;
          6. Any non-hematological toxicities (except for peripheral neuropathy as described in&#xD;
             exclusion criterion #22) that patients had from treatments in previous clinical&#xD;
             studies must have resolved to less than or equal (≤) Grade 2 by C1D1.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.&#xD;
&#xD;
          8. Adequate hepatic function within 28 days prior to C1D1:&#xD;
&#xD;
               -  For SPd, SRd, and SPEd: Total bilirubin &lt; 2* upper limit of normal (ULN) (except&#xD;
                  patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who&#xD;
                  must have a total bilirubin of ≤ 3* ULN) and both aspartate aminotransferase&#xD;
                  (AST) and alanine aminotransferase (ALT) &lt; 2.5* ULN&#xD;
&#xD;
               -  For SVd, SPVd, SDd, SNd, SBd and SDPd: Total bilirubin of &lt; 1.5* ULN (except&#xD;
                  patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who&#xD;
                  must have a total bilirubin of ≤ 3* ULN) and both AST and ALT &lt; 2.0* ULN&#xD;
&#xD;
               -  For SKd: Total bilirubin &lt; 2* ULN (except patients with Gilbert's syndrome&#xD;
                  [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3*&#xD;
                  ULN) and both AST and ALT &lt; 3.0* ULN&#xD;
&#xD;
          9. Adequate renal function within 28 days prior to C1D1. Estimated creatinine clearance&#xD;
             (CrCl) calculated using the formula of Cockroft and Gault (1976):&#xD;
&#xD;
               -  ≥ 20 milliliter per minute (mL/min) for SVd, SDd, and SKd arms&#xD;
&#xD;
               -  ≥ 30 mL/min for SNd and SBd arms&#xD;
&#xD;
               -  ≥ 45 mL/min for SPd, SPVd, SPEd and SDPd arms&#xD;
&#xD;
               -  &gt; 60 mL/min for SRd arm&#xD;
&#xD;
         10. Adequate hematopoietic function within 28 days prior to C1D1: total white blood cell&#xD;
             (WBC) count ≥ 1,500/millimeter cube (mm^3), absolute neutrophil count (ANC) ≥&#xD;
             1,000/mm^3, hemoglobin (Hb) ≥ 8.0 g/dL, and platelet count ≥ 100,000/mm^3.&#xD;
&#xD;
               -  SPVd (Arm 4) and SKd (Arm 6) only: platelet count ≥150,000.&#xD;
&#xD;
         11. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening. Female patients of childbearing potential and fertile male patients must&#xD;
             use highly effective methods of contraception throughout the study and for 1 week&#xD;
             following the last dose of study treatment.&#xD;
&#xD;
             SPd (Arm 1) Only:&#xD;
&#xD;
         12. Relapsed or refractory MM with:&#xD;
&#xD;
               1. Documented evidence of progressive disease (PD) after achieving at least stable&#xD;
                  disease (SD) for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)&#xD;
&#xD;
               2. ≤ 25 percent (%) response (i.e., patients never achieved ≥ MR) or PD during or&#xD;
                  within 60 days from the end of the most recent MM regimen (i.e., refractory MM)&#xD;
&#xD;
               3. Previously undergone ≥ 2 cycles of lenalidomide and a PI (in separate therapeutic&#xD;
                  regimens [not for maintenance] or in combination)&#xD;
&#xD;
               4. In the expansion arm at RP2D, patients must not be pomalidomide refractory&#xD;
&#xD;
             SVd (Arm 2) Only:&#xD;
&#xD;
         13. Relapsed or refractory MM with:&#xD;
&#xD;
               1. Documented evidence of relapse after ≥ 1 previous line of therapy&#xD;
&#xD;
               2. Not refractory to bortezomib in their most recent line of therapy&#xD;
&#xD;
             SRd in RRMM (Arm 3) Only:&#xD;
&#xD;
         14. Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as&#xD;
             long as patient's MM was not refractory to prior lenalidomide; patients whose MM was&#xD;
             refractory to lenalidomide maintenance regimens will be allowed in this cohort).&#xD;
&#xD;
             SPVd (Arm 4) Only:&#xD;
&#xD;
         15. Patients who received 1- 3 prior lines of therapy, including ≥ 2 cycles of&#xD;
             lenalidomide and have demonstrated disease progression on their last therapy (may&#xD;
             include prior bortezomib, as long as the patient's MM was not refractory to bortezomib&#xD;
             therapy), but patients must be pomalidomide-naïve in the Dose Expansion at RP2D&#xD;
             (Cohort 4.3 ONLY).&#xD;
&#xD;
             SDd (Arm 5) Only:&#xD;
&#xD;
         16. Patients who received ≥ 3 prior lines of therapy, including a PI and an&#xD;
             immunomodulatory agent (IMiD), or patients with MM refractory to both a PI and an&#xD;
             IMiD.&#xD;
&#xD;
         17. Patients must not have received prior anti-cluster of differentiation 38 (anti-CD38)&#xD;
             monoclonal antibodies (Cohort 5.3 ONLY - Dose Expansion at RP2D).&#xD;
&#xD;
             SKd (Arm 6) Only:&#xD;
&#xD;
         18. Patients may have received prior PIs; however, their MM must NOT be refractory to&#xD;
             carfilzomib.&#xD;
&#xD;
             SRd in NDMM (Arm 7) Only:&#xD;
&#xD;
         19. Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria&#xD;
             (calcium elevation, renal failure, anemia, lytic bone lesions) or myeloma-defining&#xD;
             events and need systemic therapy. No prior systemic therapy for NDMM is permitted&#xD;
             other than pulse dose dexamethasone (maximum dose of 160 mg) or corticosteroid&#xD;
             equivalent.&#xD;
&#xD;
             SNd (Arm 8) Only:&#xD;
&#xD;
         20. Patients must have MM that relapsed after 1 - 3 prior lines of therapy (may not&#xD;
             include those with MM refractory to bortezomib or carfilzomib but patients must be&#xD;
             ixazomib-naïve).&#xD;
&#xD;
             SPEd (Arm 9) Only:&#xD;
&#xD;
         21. Patients who received ≥ 2 prior therapies, including lenalidomide and a proteasome&#xD;
             inhibitor (in separate or the same regimens), but patients must be pomalidomide-naive&#xD;
             and elotuzumab-naive in the Dose Expansion at RP2D (Cohort 9.3 ONLY).&#xD;
&#xD;
             SBd (Arm 10) Only:&#xD;
&#xD;
         22. Patients who have MM that was refractory to an IMiD, a proteasome inhibitor, and&#xD;
             refractory or intolerant (or both) to an anti-CD38 monoclonal antibody. Patients must&#xD;
             be belantamab mafodotin-naive in the Dose Expansion cohort at RP2D (Cohort 10.3 ONLY).&#xD;
&#xD;
        SDPd (Arm 11) Only:&#xD;
&#xD;
        Patients who received 1-3 prior therapies, including lenalidomide and a proteasome&#xD;
        inhibitor (in separate or the same regimen), but patients must be pomalidomide-naive and&#xD;
        daratumumab-naive in the Dose Expansion cohort at RP2D (Cohort 11.3 ONLY).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria are not eligible to enroll in this&#xD;
        study:&#xD;
&#xD;
          1. Smoldering MM.&#xD;
&#xD;
          2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and&#xD;
             quantitative immunoglobulin levels cannot be used instead.&#xD;
&#xD;
          3. Documented active systemic amyloid light chain amyloidosis.&#xD;
&#xD;
          4. Active plasma cell leukemia.&#xD;
&#xD;
          5. Red Blood Cell (RBC) and platelet transfusions and blood growth factors within 14 days&#xD;
             of C1D1.&#xD;
&#xD;
          6. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks&#xD;
             prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on&#xD;
             long-term glucocorticoids during Screening do not require a washout period. Prior&#xD;
             radiation is permitted for treatment of fractures or to prevent fractures as well as&#xD;
             for pain management.&#xD;
&#xD;
          7. Patients with history of spinal cord compression with residual paraplegia (Dose&#xD;
             Escalation Phase only).&#xD;
&#xD;
          8. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1.&#xD;
&#xD;
          9. Prior autologous stem cell transplantation &lt; 1 month, or allogeneic stem cell&#xD;
             transplantation &lt; 3 months prior to C1D1.&#xD;
&#xD;
         10. Active graft versus host disease after allogeneic stem cell transplantation.&#xD;
&#xD;
         11. Life expectancy &lt; 3 months.&#xD;
&#xD;
         12. Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
         13. Active, unstable cardiovascular function:&#xD;
&#xD;
               1. Symptomatic ischemia, or&#xD;
&#xD;
               2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with&#xD;
                  ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree&#xD;
                  atrioventricular (AV) block or asymptomatic left anterior fascicular block/right&#xD;
                  bundle branch block (LAFB/RBBB) will not be excluded), or&#xD;
&#xD;
               3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or&#xD;
&#xD;
               4. Myocardial infarction (MI) within 3 months prior to C1D1&#xD;
&#xD;
               5. Ejection fraction (EF) &lt; 50% at Screening&#xD;
&#xD;
         14. Uncontrolled active hypertension.&#xD;
&#xD;
         15. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within one week prior to first dose.&#xD;
&#xD;
         16. Known active hepatitis A, B or C.&#xD;
&#xD;
         17. Known human immunodeficiency virus (HIV) infection or HIV seropositivity.&#xD;
&#xD;
         18. Any active gastrointestinal dysfunction that prevents the patient from swallowing&#xD;
             tablets or interferes with absorption of study treatment.&#xD;
&#xD;
         19. Currently pregnant or breastfeeding.&#xD;
&#xD;
         20. A serious active psychiatric or active medical condition which, in the opinion of the&#xD;
             Investigator, could interfere with treatment.&#xD;
&#xD;
         21. Hypersensitivity to any of the treatments for the arm in which the patient is&#xD;
             enrolled.&#xD;
&#xD;
         22. SVd Arm (Arm 2), SPVd (Arm 4), and SNd Arm (Arm 8) only: Prior history of neuropathy&#xD;
             Grade &gt; 2, or Grade ≥ 2 neuropathy with pain at Screening (within 28 days prior to&#xD;
             C1D1).&#xD;
&#xD;
         23. Patients who are eligible for the selinexor PK Run-in only: Treatment with moderate or&#xD;
             strong inhibitors/inducers of CYP3A within 7 days prior to Day 1 of the PK Run-in&#xD;
             period.&#xD;
&#xD;
         24. Patients who are eligible for the selinexor PK Run-in only: Not able to receive a&#xD;
             strong CYP3A4 inhibitor due to concomitant medications.&#xD;
&#xD;
         25. SKd arm only: HBs Ag + plus HBc Ab + even though no active hepatitis B virus (HBV)&#xD;
             hepatitis. If HBs Ag - plus HBc Ab +, treating physician needs to contact the medical&#xD;
             monitor.&#xD;
&#xD;
         26. Prior exposure to a selective inhibitor of nuclear export (SINE) compound, including&#xD;
             selinexor.&#xD;
&#xD;
             SBd (Arm 10): Only:&#xD;
&#xD;
         27. Current corneal epithelial disease except mild punctate keratopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <email>SShacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumit Madan, MD</last_name>
      <email>Sumit.Madan@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Sumit Madan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jonnsson Comprehensive Cancer Center / University of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>0095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <phone>888-798-0719</phone>
      <email>GSchiller@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schiller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon-Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Schade, MD</last_name>
      <email>Henning.Schade@healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Henning Schade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Branagan, MD</last_name>
      <phone>617-724-4000</phone>
      <email>abranagan@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Branagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifton Mo, MD</last_name>
      <phone>617-582-7969</phone>
      <email>Clifton_Mo@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Clifton Mo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhamed Baljevic, MD</last_name>
      <email>muhamed.baljevic@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Muhamed Baljevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noa Biran, MD</last_name>
      <phone>551-996-8704</phone>
      <email>Noa.Biran@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Noa Biran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <phone>212-305-5065</phone>
      <email>CTOInformation@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Lentzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine / NewYork Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Rossi, MD</last_name>
      <email>adr9009@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Adriana Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilmot Cancer Center/ University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brea Lipe, MD</last_name>
      <email>Brea_Lipe@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Brea Lipe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha Alexander Tuchman, MD, MHS</last_name>
      <phone>984-974-0000</phone>
      <email>sascha_tuchman@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Sascha Alexander Tuchman, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Institute of Cancer/ Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
      <phone>919-668-1017</phone>
      <email>gaspa001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon- Tennessee Oncology Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, MD</last_name>
      <phone>615-986-7602</phone>
      <email>jberdeja@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Berdeja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Callander, MD</last_name>
      <phone>608-265-8554</phone>
      <email>nsc@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Natalie Callander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center/Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar Bahlis, MD</last_name>
      <phone>+1 (403) 944-1880</phone>
      <email>nbahlis@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Nizar Bahlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute / University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Venner</last_name>
      <phone>780-432-8771</phone>
    </contact>
    <investigator>
      <last_name>Chris Venner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver,</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrell White</last_name>
    </contact>
    <investigator>
      <last_name>Darrell White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Dean</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>5241</phone_ext>
    </contact>
    <investigator>
      <last_name>Christine Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital / McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selinexor</keyword>
  <keyword>KCP-330</keyword>
  <keyword>STOMP</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Ixazomib</keyword>
  <keyword>Elotuzumab</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Belantamab mafodotin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

